Physician profile
Robert Bock
NPI 1245251891
$2,227.10
in general payments reported to CMS, 2019-2025
21 companies · $713 in 2025
The $713 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $128 · 2023: $333 · 2024: $803 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $619.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $292.51 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $219.59 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $162.08 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $159.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $138.69 | 2019-2024 | |
| Astellas Pharma US INC | $134.13 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $100.72 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $96.60 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $79.13 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $34.62 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $28.81 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $28.71 | 2019-2020 | |
| Abbvie INC. | $19.72 | 2023 | Ubrelvy |
| Cagent Vascular INC | $19.00 | 2025 | Serrantor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.45 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $16.28 | 2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $15.60 | 2023 | Gvoke Hypopen |
| Azurity Pharmaceuticals, INC. | $15.14 | 2024 | Horizant |
| Phathom Pharmaceuticals, INC. | $14.35 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.